GLP-1 analogues or DPPIV inhibitors (thereby increasing the availability of endogenous GLP-1) are already licenced for use in type 2 diabetes and the relevant data regarding NAFLD are discussed above. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.